Next Article in Journal
Evaluation of a Hydrogel-Based Diagnostic Approach for the Point-of-Care Based Detection of Neisseria gonorrhoeae
Next Article in Special Issue
Silver Nanoparticles and Polyphenol Inclusion Compounds Composites for Phytophthora cinnamomi Mycelial Growth Inhibition
Previous Article in Journal / Special Issue
Microwave-Assisted Green Synthesis of Silver Nanoparticles Using Juglans regia Leaf Extract and Evaluation of Their Physico-Chemical and Antibacterial Properties
Article Menu

Export Article

Open AccessReview
Antibiotics 2018, 7(3), 69;

Biogenic Nanosilver against Multidrug-Resistant Bacteria (MDRB)

Laboratory of Chemical Biology, Institute of Chemistry, State University of Campinas, Campinas 13083-970, Brazil
Present address: School of Bioprocess and Chemical Engineering, University College Dublin, Dublin D04 V1W8, Ireland
Author to whom correspondence should be addressed.
Received: 28 June 2018 / Accepted: 31 July 2018 / Published: 2 August 2018
(This article belongs to the Special Issue Silver-Based Antimicrobials)
Full-Text   |   PDF [1846 KB, uploaded 2 August 2018]   |  


Multidrug-resistant bacteria (MDRB) are extremely dangerous and bring a serious threat to health care systems as they can survive an attack from almost any drug. The bacteria’s adaptive way of living with the use of antimicrobials and antibiotics caused them to modify and prevail in hostile conditions by creating resistance to known antibiotics or their combinations. The emergence of nanomaterials as new antimicrobials introduces a new paradigm for antibiotic use in various fields. For example, silver nanoparticles (AgNPs) are the oldest nanomaterial used for bactericide and bacteriostatic purposes. However, for just a few decades these have been produced in a biogenic or bio-based fashion. This review brings the latest reports on biogenic AgNPs in the combat against MDRB. Some antimicrobial mechanisms and possible silver resistance traits acquired by bacteria are also presented. Hopefully, novel AgNPs-containing products might be designed against MDR bacterial infections. View Full-Text
Keywords: silver nanoparticles; biological synthesis; multidrug-resistant bacteria silver nanoparticles; biological synthesis; multidrug-resistant bacteria

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Barros, C.H.N.; Fulaz, S.; Stanisic, D.; Tasic, L. Biogenic Nanosilver against Multidrug-Resistant Bacteria (MDRB). Antibiotics 2018, 7, 69.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Antibiotics EISSN 2079-6382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top